GENE ONLINE|News &
Opinion
Blog

2025-12-01|

Substance P Identified as Key Driver of Immune Imbalance in Chronic Allergic Conjunctivitis

by GOAI
Share To

Researchers investigating chronic allergic conjunctivitis have identified substance P, a neuropeptide associated with inflammation and pain, as a key factor in immune system imbalances and damage to the ocular surface. The study, conducted by Bao et al., highlights the role of substance P in influencing the balance between Th17 cells and regulatory T cells (Tregs), two critical components of the immune system. This imbalance is linked to inflammation and tissue damage observed in chronic allergic eye conditions.

The findings suggest that substance P contributes to an increase in Th17 cell activity while suppressing Treg function, creating an environment conducive to prolonged inflammation. This dysregulation may exacerbate ocular surface damage commonly seen in patients with chronic allergic conjunctivitis. The research provides further insight into the underlying mechanisms driving immune responses in such conditions and underscores the potential impact of neuropeptides like substance P on both immune regulation and tissue health.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top